---
title: "Taysha Gene Therapies to present REVEAL Phase 1/2 data for Rett gene therapy TSHA-102 at 2026 IRSF meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290873833.md"
description: "Taysha Gene Therapies will present REVEAL Phase 1/2 data for its Rett syndrome gene therapy, TSHA-102, at the 2026 IRSF meeting. Updates include long-term safety and efficacy results across pediatric and adolescent/adult cohorts from REVEAL Part A. A natural history analysis identified a developmental plateau after age 6, supporting the trial population. Additionally, new validation work supports using developmental milestone assessment as an FDA-supported primary endpoint for single-arm interventional studies."
datetime: "2026-06-25T20:01:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290873833.md)
  - [en](https://longbridge.com/en/news/290873833.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290873833.md)
---

# Taysha Gene Therapies to present REVEAL Phase 1/2 data for Rett gene therapy TSHA-102 at 2026 IRSF meeting

-   Taysha Gene Therapies flagged new updates for TSHA-102 in Rett syndrome ahead of the 2026 IRSF scientific meeting, June 29 to July 1. \* Longer-term data from REVEAL Part A were already disclosed, showing broad functional improvements that deepened over at least 12 months. \* Additional REVEAL Part A safety and efficacy results will be presented June 30, spanning pediatric plus adolescent/adult cohorts. \* A natural history analysis found a developmental plateau after age 6, supporting a stable population for the planned REVEAL pivotal trial. \* New validation work supports the developmental milestone assessment as an FDA-supported primary endpoint for single-arm interventional studies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606251601PRIMZONEFULLFEED9752893) on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md)

## Related News & Research

- [Taysha Gene Therapies taps Catalent for TSHA-102 Rett syndrome commercial manufacturing support](https://longbridge.com/en/news/294689795.md)
- [Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome](https://longbridge.com/en/news/293788160.md)
- [CMS grants NTAP reimbursement status for Abeona gene therapy ZEVASKYN under FY2027 IPPS rule](https://longbridge.com/en/news/294816144.md)
- [Opus Genetics completes enrollment in Phase 3 trial of OPGx-LCA5 gene therapy for LCA5 retinal disease](https://longbridge.com/en/news/294682847.md)
- [08:17 ETGenezen and the Raiden Science Foundation Announce Partnership for AAV9 Gene Replacement Therapy for UBA5 Clinical Trial](https://longbridge.com/en/news/294692192.md)